LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
49.01
-2.12 (-4.15%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide.

The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments.

The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices.

The Advanced Circulatory Support segment develops, produces, and sells temporary life support products.

It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers.

The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

LivaNova PLC
LivaNova logo
Country United Kingdom
Founded 1987
IPO Date Feb 10, 1993
Industry Medical Devices
Sector Healthcare
Employees 2,900
CEO Vladimir Makatsaria

Contact Details

Address:
20 Eastbourne Terrace
London, W2 6LG
United Kingdom
Phone 44 20 3325 0660
Website livanova.com

Stock Details

Ticker Symbol LIVN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001639691
CUSIP Number G5509L101
ISIN Number GB00BYMT0J19
Employer ID 98-1268150
SIC Code 3845

Key Executives

Name Position
Vladimir A. Makatsaria Chief Executive Officer and Director
Alex Shvartsburg Chief Financial Officer
Michael D. Hutchinson Senior Vice President, Chief Legal Officer and Company Secretary
Lindsey Little Senior Director of Investor Relations
Deanna Wilke Vice President of Corporate Communications
Matthew Joseph Dodds III Senior Vice President of Corporate Development and IT
Paul R. Buckman President of Advanced Circulatory Support and GM of Transcatheter Mitral Valve Replacement
Stephanie Bolton President of Global Epilepsy
Ahmet Tezel Ph.D. Chief Innovation Officer
Franco Poletti President of Cardiopulmonary Business Unit

Latest SEC Filings

Date Type Title
Nov 1, 2024 8-K Current Report
Oct 31, 2024 IRANNOTICE Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012
Oct 31, 2024 10-Q Quarterly Report
Oct 30, 2024 8-K Current Report
Oct 8, 2024 8-K Current Report
Sep 11, 2024 144 Filing
Sep 10, 2024 8-K Current Report
Aug 1, 2024 IRANNOTICE Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012
Aug 1, 2024 10-Q Quarterly Report
Jul 31, 2024 8-K Current Report